Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-cash Items (2020 - 2025)

Insight Molecular Diagnostics' Non-cash Items history spans 4 years, with the latest figure at $306000.0 for Q3 2025.

  • For Q3 2025, Non-cash Items rose 33.62% year-over-year to $306000.0; the TTM value through Sep 2025 reached $306000.0, up 33.62%, while the annual FY2021 figure was $19.1 million, 135.8% up from the prior year.
  • Non-cash Items for Q3 2025 was $306000.0 at Insight Molecular Diagnostics, down from $390000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $19.1 million in Q4 2021 and bottomed at $51.0 in Q2 2024.
  • The 3-year median for Non-cash Items is $229000.0 (2024), against an average of $2.9 million.
  • The largest YoY upside for Non-cash Items was 764605.88% in 2025 against a maximum downside of 28.5% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $19.1 million in 2021, then plummeted by 98.8% to $229000.0 in 2024, then surged by 33.62% to $306000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Non-cash Items are $306000.0 (Q3 2025), $390000.0 (Q2 2025), and $138000.0 (Q1 2025).